Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema).

It is an interleukin-13 antagonist, given by subcutaneous injection.

Lebrikizumab blocks interleukin 13 (IL-13), a cytokine that is produced by Th2 cells.

The most common side effects include injection site reactions, dry eye and conjunctivitis , including allergic conjunctivitis.

Lebrikizumab was approved to treat moderate-to-severe atopic dermatitis.

Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents twelve years and older with a body weight of at least 40 kilograms (88 lb) who are candidates for systemic therapy.

IL-13 is thought to induce the expression of signalling protein, periostin, by epithelial cells of the bronchi.

Periostin has a role in a number of asthma related problems, such as bronchial hyperresponsiveness, inflammation, and activation and proliferation of airway fibroblasts, which are involved in airway remodelling.

Patients with high periostin levels responded significantly better to lebrikizumab in the phase II study: the forced expiratory volume in 1 second (FEV1) was 8.2% higher than under placebo.

Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids.